MacroGenics Resumes LINNET Trial After FDA Hold Lifted

The latest announcement is out from MacroGenics ( (MGNX) ).

On April 8, 2026, MacroGenics, Inc. announced that the U.S. Food and Drug Administration removed the partial clinical hold on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers, allowing the company to resume enrollment of new participants. During the hold, previously enrolled patients continued treatment, and going forward the trial will proceed under a revised protocol that adds risk-mitigation measures for potential hematologic and cardiac toxicities.

The LINNET study is testing single-agent lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, in up to about 60 patients with platinum-resistant ovarian cancer or clear cell gynecologic cancer who have received at least one prior therapy. MacroGenics reported that 41 participants have already been dosed in LINNET and more than 300 patients have received lorigerlimab across Phase 1 and Phase 2 trials, underscoring the program’s clinical maturity and the importance of the FDA’s decision for the company’s oncology pipeline and stakeholders.

The most recent analyst rating on (MGNX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.

Spark’s Take on MGNX Stock

According to Spark, TipRanks’ AI Analyst, MGNX is a Neutral.

The score is driven primarily by weak financial performance (ongoing losses and significant cash burn) and a negative regulatory event (partial clinical hold tied to serious safety issues). Technicals are supportive via strong trend and positive MACD, but extremely overbought readings increase downside risk. Valuation is constrained by a negative P/E and no dividend yield data.

To see Spark’s full report on MGNX stock, click here.

More about MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Rockville, Md.-based company builds its pipeline from proprietary next-generation antibody platforms, leveraging its protein engineering expertise to advance candidates and secure strategic collaborations with global pharmaceutical and biotechnology partners.

The company’s technology suite underpins programs such as its bispecific DART molecules, designed to engage multiple targets in oncology. These platforms are intended to be broadly applicable across therapeutic domains, positioning MacroGenics as a specialist in complex antibody engineering with a focus on immuno-oncology and partnership-driven development.

Average Trading Volume: 1,090,324

Technical Sentiment Signal: Hold

Current Market Cap: $212.9M

See more data about MGNX stock on TipRanks’ Stock Analysis page.